Further, lentiviral delivery of CRISPR/Cas9 targeting BCR-ABL significantly inhibits myelogenous leukemia cell growth and tumorigenesis, so therapies based on ABL gene editing may provide a potential strategy for imatinib-resistant chronic myeloid leukemia patients [137]. This evidence concerns the gene ABL1 and myeloid leukemia.